Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

GVHD Prophylaxis

Jaap Jan Boelens  1 , Francesca Bonifazi  2 , Lars Klingen Gjærde  3 , David Michonneau  4   5   6 , Annalisa Ruggeri  7 , Laura Saavedra  8 , Gérard Socié  4   5   6
Anna Sureda  1 , Selim Corbacioglu  2 , Raffaella Greco  3 , Nicolaus Kröger  4 , Enric Carreras  5
, editors.
In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 26.
.
Affiliations
Free Books & Documents
Review

GVHD Prophylaxis

Jaap Jan Boelens et al.
Free Books & Documents

Excerpt

A potentially life-threatening complication of allo-HCT is graft-versus-host disease (GVHD), which occurs when T-cells from the recipient recognize host antigens on healthy tissues. Despite 50 years of history and over half a million procedures performed worldwide, GVHD remains a challenging issue that physicians are facing on a daily basis.

PubMed Disclaimer

References

    1. Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9(2):e111–20. - PubMed
    1. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942–7. - PubMed
    1. Battipaglia G, Labopin M, Blaise D, Diez-Martin JL, Bazarbachi A, Vitek A, et al. Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post-transplantation cyclophosphamide alone in acute myelogenous leukemia: a retrospective study on behalf of the acute leukemia working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2022;28(9):587.e1–7. - PubMed
    1. Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022;40(11):1174–85. - PMC - PubMed
    1. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6(3):e132–43. - PMC - PubMed

LinkOut - more resources